Alpha Cognition Issues 25,000 Inducement Options to New Hire
Alpha Cognition granted 25,000 stock options to a new non-executive employee under Nasdaq Rule 5635(c)(4), with an exercise price set at the September 8 closing rate.
Alpha Cognition Inc. (NASDAQ: ACOG) approved the issuance of nonstatutory stock options for 25,000 shares of common stock to a new non-executive employee. The Compensation Committee authorized the award on September 8, 2026, classifying it as an inducement grant material to the individual’s decision to join the company. This action complies with Nasdaq Listing Rule 5635(c)(4), which permits specific equity grants to new hires without shareholder approval, provided they are not current employees.
The options carry an exercise price of $9.52 per share, matching the closing price of Alpha Cognition’s common stock on the grant date. The company’s 2026 Inducement Grant Plan restricts these awards exclusively to individuals who were not previously employed by Alpha Cognition. This mechanism allows the biopharmaceutical firm to attract specialized talent for its pipeline development while maintaining compliance with exchange listing requirements.
Vesting Structure Tied to Continued Service
The equity award vests over a three-year period contingent on the employee’s continued service relationship with Alpha Cognition. One-third of the options vest at the first anniversary of the grant date. The remaining two-thirds vest in equal quarterly installments over the subsequent two years. This schedule aligns the new hire’s financial incentives with long-term retention and ongoing contribution to the company’s operational goals.
Pipeline Context for Neurodegenerative Treatments
Alpha Cognition is a commercial-stage biopharmaceutical company focused on therapies for Alzheimer’s disease and cognitive impairment associated with mild traumatic brain injury. The company’s lead product, ZUNVEYL, is a patented acetylcholinesterase inhibitor designed to minimize gastrointestinal side effects. Its active metabolite distinguishes itself from existing treatments like donepezil by binding to neuronal nicotinic receptors, specifically the alpha-7 subtype, which is linked to positive cognitive effects.
Strategic Focus on Novel Formulations
Beyond ZUNVEYL, Alpha Cognition is developing ALPHA-1062 for use in combination with memantine to address moderate to severe Alzheimer’s dementia. The company is also advancing an intranasal formulation for cognitive impairment resulting from mild traumatic brain injury. These efforts target conditions with currently no approved treatment options, positioning the firm to address significant unmet medical needs in the neurodegenerative disease market.
